Metallization device and method

ABSTRACT

The present invention concerns a topical formulation for the treatment of cellulite, comprising alfalfa herb and derivatives thereof and can further comprise melatonine. 
     The invention refers also to a method of application of said formulation and to a pharmaceutical kit for the treatment of cellulite comprising said formulation, together with vegetal or mineral mud.

The present invention concerns a topical formulation for the treatment of cellulite.

More in particular, the invention refers to a creamy pharmaceutical formulation, suitable to be administered cutaneously, preferably in association with thermal muds.

It is known that cellulite is a disease that interests the hypoderm, tissue of a predominantly adipose nature placed between the derm and the underlying muscular layer, of some specific anatomic regions in women and men.

Cellulite reveals through the typical aspect “orange peel” of the skin and is due to the increase in the subcutaneous layer of the number and dimension of the cells of fat positioned below the derm.

It is commonly agreed that one of the most important causes of the appearance of cellulite is the reduced vascularization of the muscular layer placed just below the adipose component. The reduction of the vascularization causes the reduction of the coming of lipoilstic hormonal signals to the superficial fat. Moreover, for this reason the superficial fat responds weakly to therapeutical attempts.

Cellulite is a disease having an evolutive character, which develops on a constitutional soil prepared by anatomical, hormonal and metaboilsc features, on which rousing events operate such as a wrong diet, sedentariness, venous pathologies and hormonal therapies.

A certain relation exists between the appearance or the aggravation of cellulite and some hormonal imbalance, interpreted not as real pathologies, but as the reduced function of some glands, such as thyroid or endocrine pancreas, caused for example by an increased production of insulin, stimulated by an excess of sugars, the taking of extroprogestinics for therapeutical or contraceptive aims, the therapeutical taking of cortisonics or by an abnormal surrenalic response to different stressing stimula.

It is also agreed a tight link between food, wellbeing and cellulite, passing through the maintenance of the balance between a correct alimentation and hormonal function.

The requirements for the appearance of cellulite in the interested regions are caused by the coexistence of problems of the venous and lymphatic microcirculation.

At present, different kind of treatment exist for this disease, including treatments of exclusive competence of a physician, such as for example all those methods providing for the subcutaneous infiltration of substances having a draining and/or reducing effect, aesthetic treatments, such as for example massages, lymphodraining, electrostimulation, and also product for a “do it yourself” application, such as for example creams or gels performing a draining, lipolytic and vasoprotective action.

In particular products of the kind “do-it-yourself” are particularly widespread, both for the easiness of application and for the reduced costs.

Nevertheless, the results that can be obtained through this kind of products are very limited, since they can not act directly on the causes of the insurgency of cellulite, but simply try to conceal its effects.

It would be much better to dispose of a pharmaceutical formulation, for topical use, that can be easily applied to the body in a “do-it-yourself” way, but allowing to achieve really appreciable results.

These and other results are obtained according to the present invention by providing for a creamy pharmaceutical formulation, suitable to be administered cutaneously, the action of which is based on the combination of two active principles never used before for this kind of treatment.

An aim of the present invention is therefore that of providing a pharmaceutical formulation allowing to overcome the limits of the anti-cellulite products according to the prior art and to obtain the results described previously.

A further aim of the invention is that said formulation can be realised with substantially limited costs, as far as both the costs of the used compounds and the costs of production is concerned.

It is therefore a first specific object of the present invention a topical formulation for the treatment of cellulite comprising alfalfa herb and derivatives thereof and preferably melatonine.

In particular, according to the invention, said alfalfa herb derivatives comprise the Pyro-Glu-Tyr-Proamide tripeptide.

According to the present invention, said alfalfa herb is present according to a concentration comprised between 5 and 40% (preferably between 10 and 20%) by weight and the concentration of said melatonine is comprised in a range between 0 and 0.1% by weight, and preferably is comprised in a range between 0.01 and 0.05% by weight.

Moreover, according to the invention, said formulation further comprises water, excipients and other natural substances, chosen amongst ginkgo bilobate, avocado, blueberry, centella, fucus, glycerine, caffeine, extract of Centella asiatica, escina, tocopherol, dextrin, lecithin, tocopherol acetate, phospholipids, cyclodextrins, oils and natural active principles.

Further it is a second specific object of the present invention a method for the application of a topical formulation for the treatment of cellulite as previously defined, wherein said formulation is applied on the skin, in the zones interested by cellulite and/or localised adiposity, by massaging until the complete absorption of the formulation.

Preferably, according to the invention, after the application of said formulation, on the zones of skin previously treated vegetal or mineral mud is applied, in case enriched with melatonine and/or alfalfa herb, and further with excipients chosen between ginkgo bilobate, avocado, blueberry, centella, fucus, zinc oxide, glycerine, caffeine, tocopherol, lecithin, waterpuncite, silica aluminate, sepiolite, essences and natural active principles, seaweeds, active thermal water.

Moreover it is a further specific object of the present invention a pharmaceutical kit for the treatment of cellulite comprising a formulation as previously defined, together with vegetal or mineral mud, preferably charged with alfalfa herb and even more preferably also with melatonine.

Further, said vegetal or mineral mud can further comprise excipients chosen between ginkgo bilobate, avocado, blueberry, centella, fucus, zinc oxide, glycerine, caffeine, tocopherol, lecithin, waterpuncite, silica aluminate, sepiolite, essences and natural active principles, seaweeds, active thermal water.

Finally, according to the invention in the mud of said pharmaceutical kit said alfalfa herb is preferably present according to a concentration comprised between 5 and 10% by weight and said melatonine is present according to a concentration comprised between 0.001 and 0.005% by weight.

The invention will be described in the following for illustrative, non-limitative purposes, with particular reference to some illustrative examples.

The pharmaceutical formulation for the treatment of cellulite according to the present invention presents itself as a cream for topical application.

The cutaneous and transdermic administration of substances or medicaments is a very common way of administration of pharmaceuticals and medicaments, very practical and in some cases it represents the primary choise due to the immediate effectiveness and the good general tolerability. The active principle is applied on the interested skin according to preset procedures, such as for example aspersion or massages, in order to ease a homogeneous distribution and penetration in the pores of the skin down to the deeper layers of the subcutis and of the derma.

EXAMPLE 1 Characterization of the Active Principles of the Formulation

Active principles contained in the cream are alfalfa herb and melatonine of vegetal origin.

Alfalfa herb, or medicago sativa or medical herb, belongs to the family of leguminosae, and is generally used as nourishment for herbivores. It is rich of minerals, it is valuable for its high content in vitamin A, a vitamin that is liposoluble in fats, and consequently remains substantially unimpaired also when it is dried, for 100 grams of medical herb 8000 U.I. of vitamin A are obtained. It is a good source of pyridoxine, one of the vitamins of the B complex, and of vitamin E, it is rich of vitamin K and also of proteins, containing a percentage by weight of 18.9%.

Alfalfa herb contains also soluble and insoluble fibres, saponins, medicagenic acid, phytoestrogens, coumestrol, pigments, antioxidant activity, β-carotene, chlorophyl, mineral salts, other vitamins, in particular vitamins C, D, K, B1, B2, B3, B5, B6, B8, B12, folic acid. It is also rich in aminoacids.

It further contains high amounts of some coumarinic and mineral derivatives such as phosphorus, silicium, sodium, potassium, calcium, magnesium, boron, iron, manganese, copper, cobalt and sulfur.

Moreover, alfalfa herb contains also triterpenic saponins, eteroxides, proteins; its aerial parts contain coumestrol, a structure similar to the extradiol, with estrogenic features.

In addition to the vitamins and minerals, alfalfa herb contains also enzymes, coumestrol, isoflavones and phytoestrogens, and alcaloids such as asparagine and trigonelline.

Amongst the known effects of alfalfa herb is well acknowledged ipolipenic effect. In particular alfalfa herb prevents the formation of atheroma in presence of ipercholesterolemy.

The second fundamental active principle of the formulation according to the present invention is melatonine.

Melatonine is produced by the pineal gland under control of the light and is mainly excreted by night. Its excretion profile defines the biological night. light also determines different non visual response, such as the phase shift of the internal biological clock by increasing care, heart frequency and pupylar constriction. Both esogen melatonine and light, if suitably administered, can therefore modify the human circadian rhythm. These effects of melatonine and light are defined chronobiotic effects and are used to relieve troubles of the circadian rhythms, such as for example those due to jetlag, night working turns, and some sleep disorders.

Most of the physiological parameters (body temperature, hormones and electrolytes) and behavioural parameters (mood, alimentation, surveillance, sleep and performance) show circadian rhythms.

Circadian rhythms are endogenous rhythms with a periodicity of about 24 hours remaining constant in constant ambient condition (light, temperature and posture). The endogenous circadian timing system allows to the body to anticipate daily modifiedons of the environment. Circadian rhythms are generated by a pacemaker positioned in the superchiasmatic hypotalamic nucleus (SNC), the damaging of these nuclei produces arhythmicity in different controlled systems. Synchronization of such rhythms allows the regular development of the common daily activities (sleep and alimentation).

Ocular light is the highest stimulus responsible of the synchronization of the circadian system in man. Even if also other stimula can act as a pacemaker for the internal clock (alimentation, activity and sleep), light is the stronger primary system of regulation.

The production of endogenous melatonine is intimately linked to the circadian timing system. The rhythm of synthesis of melatonine is controlled by the superchiasmatic nucleus (SNC) by means of a multisynaptic way (SNC—paraventricular nucleum PVN—upper cervical ganglium—rilease of noradrenaline from postgangliar fibres in the pineal gland).

The production of melatonine is highest during darkness in all studied animal species.

Melatonine is metabolized mainly in liver through the cytocrom P450 transforming it in 6 hydroxymelatonine. It is then conjugated with sulphate to form 6 sulphatoxymelatonine and in minor part with glycuronic acid.

Time period of the rhythm of the melatonine is considered the most reliable detector of the biological clock. Melatonine, in plasma or also in saliva, provides for a suitable and reliable instrument for long time monitoring of the human circadian system, both in laboratory and in real life.

The synthesis of melatonine is influenced by a plurality of factors, for example by physical activity, sleep, time of meals and kind of meals, stress, menstrual cycle. On the contrary, other circadian rhythms, such as body internal temperature and cortisol excretion, were significantly modified by these factors.

Melatonine is a strong antioxidant with a very good action of stimulus of the immunitary system. It has an important role together with other substances in maintaining the equilibrium of the neuro-immuno-endocrinous system.

EXAMPLE 2 Characterization of the Mud Applicable after the Formulation According to the Invention

In a preferred embodiment of the present invention, the action of the melatonine and alfalfa herb based product administered cutaneously for the treatment of the cellulite is followed by the application of thermal muds on the same region of skin (in particular those coming from Abano-Montegrotto Terme were tested and proved to be particularly suitable) exploited because of their ability to act as a natural bio-reactor that can favor the trans-dermic passage of the cutaneously administered medicaments, with the aim of increasing the therapeutical effect.

Thermal medicine has an ancient tradition in treatment of a number of muscular-sinew, articular, skeletal and metabolic pathologies, it is predominantly used in neurology, orthopaedics and traumatology, rheumatology, endocrinology, otorino etc., in each of these sectors of medicine finding specifical indication with documented clinical results.

Generally, by bioreactor it is intended a container having specific functions, which is able to subject biological material possibly contained in it to influences of a chemical, physical, thermal and mechanical nature determining change of state or composition or structure of the biological material.

Some thermal muds, because of the specular features they have, can be compared to a natural bioreactor, that is able to subject the individual to chemical, physical, thermal and mechanical stimulations taking place at the same time, so to cause anatomical physiological, metabolic and functional modifications at the level of skin and derma superficial layers.

The application of the pharmaceutical formulation of the invention and the subsequent application of a layer of thermal mud on the skin regions where the formulation had been previously applied determine a faster trans-dermal passage of the pharmaceutical exalting the ability of the thermal mud because of its intrinsic quality and especially for biological effect of the bio-reactor defined in the application area.

In particular, Abano Montegrotto thermal mud is prepared by collecting clay from the bottom of two thermal lakes and putting it in vessels for the maturation period, developing in two months in presence of a continuous flux of thermal water at a temperature of 85°-87° C. During this maturation process, muds are colonized by cianobacteria and microseaweeds giving it specific chemical-physical features. The features of this thermal mud are known thanks to a plurality of scientific publication in particular by University of Padova, Faculty of Medicine and collected by the Centro Studi Termali “Pietro D'Abano”.

Clay changes into mature muds thus increasing its lipidic and water content, increasing thermal thermoinsulation, with the appearance of diatomeae and cyanoficeae, seaweeds present in Abano-Montegrotto thermal ecosystem and especially a bacterial colonization of micro-organism, in particular cyanobacteria amongst which Phormidium.

In particular this cyanobacterium is able to produce glycolipids substances performing a fundamental role in the therapeutical action of the thermal mud. Features of the mature thermal mud are evaluated taking into consideration the visco-elastic and structural features constituting the rheological plant of the muds (RTM index, for the definition of which Italian patents N. IT1268654 and IT1282836, herein incorporated by reference, can be seen). Bioadhesivity of the muds to the skin and the tensiometric features of the thermal mud for the skin (TVS, for the definition of which Bettero A., of Benedetto M., Marcazzan M., Zancato M. and Semenzato A. (1998), An innovative technical form for bioadhesive topical application of active substances, Proc.XXth IFSCC, Cannes; Bettero A., Marcazzan M., Gregorio M. and Semenzato A. (1999), Nuove forme tecniche per l'applicazione topica bioadesiva e metodo per valutare in vivo and in vitro l'effetto bioadesivo indotto (Bioadhesivity test TVS), Atti Cony. Argille curative, Salice Terme/PV, October 26-28, pp. 145) and is measured by evaluating the superficial free energy and polar component of the muds.

The application of hot mature muds on the skin, at a temperature of 38-39° C., determines: an increase of the skin temperature of about 2-5° C., an increase of the temperature of the subskin and of the derm of about 1-3° C., an increase of the muscular sinew temperature and in particular of about 1-2° C. From all of these a vasodilatation of the zones interested by the increase in temperature, with better district vascularization and increase in cell metabolic exchanges.

It is determined an increase of ionic exchanges through the skin in both eisotrope and ectotrope direction, mechanism that is very importante for the aims of the present invention.

At a systemic level it is detected a light increase of the cardial frequency, increase of the body temperature, sweeping, skin vasodilatation, decreased concentration of oxyemoglobine in the venous blog, enzimatic activation, decreasing of the level of creatinine, triglicerides, cortisol, alcalic phosphatasi. Renal functionality improves and with sudoration decrease the quality of circulating liquid, with a better redistribution of the intra and extracellular liquids.

The effect of the muds therapy causes a neuro-immuno endocrinous reply manifested by an important increase in the blood of ACTH and beta endorfine.

This chain of physical and biochemical and biohormonal events is nothing but the effect of the natural bioreactor happening in the thermal site.

EXAMPLE 3 Preparation of a First Formulation According to the Invention

An amount of 100 g of a creamy formulation according to the present invention was prepared by mixing together at ambient temperature 10 g of alfalfa herb in form of dry extract and derivatives thereof, in particular Pyro-Glu-Tyr-Proamide tripeptide (5 μg), and an amount of 10 mg of melatonine, together with water and other excipients and other natural substances, in particular chosen amongst ginkgo bilobate, avocado, blueberry, centella, fucus, glycerine, caffeine, extract of Centella asiatica, escina, tocopherol, dextrin, lecithin, tocopherol acetate, phospholipids, cyclodextrins, oils and natural active principles. Components were mixed until a homogeneous creamy compound was obtained.

EXAMPLE 4 Preparation of a Second Formulation According to the Invention

An amount of 100 g of a creamy formulation according to the present invention was prepared mixing together at ambient temperature 20 g of alfalfa herb in form of dry extract and derivatives thereof, in particular Pyro-Glu-Tyr-Proamide tripeptide (10 μg), and an amount of 10 mg of melatonine, together with water and other excipients and other natural substances, in particular chosen amongst ginkgo bilobate, avocado, blueberry, centella, fucus, glycerine, caffeine, extract of Centella asiatica, escina, tocopherol, dextrin, lecithin, tocopherol acetate, phospholipids, cyclodextrins, oils and natural active principles. Components were mixed until a homogeneous creamy compound was obtained.

EXAMPLE 5 Application of the Formulation According to the Invention

The formulation (cream) based on alfalfa herb and melatonine according to the invention is applied on the skin, in a zone interested by cellulite and/or localized adiposity, according to an amount depending on the width of the zone itself and the capacity of absorption of the skin. The interested body zone must be massaged in order to allow for a better and more homogeneous distribution of the product on the surface of the skin, the massage allowing for absorption and transdermic passage of some components of the used product, and at the same time the massage having the effect of stimulating the vascularization of the subcutaneous tissue with manual mechanical compressions making easier the ematic support to tissues and venous coming back and lymphatic of drain from deep zones. This aspect is fundamental for the efficacy of the product.

In a second step, according to a preferred embodiment of the present invention, on the zones of skin previously treated was applied an homogeneous layer having a thickness of some millimetres of Abano Montegrotto thermal mud or anyway of other vegetal or mineral muds enriched with the same active principles (melatonine (0.005% by weight) and alfalfa herb (5-10% by weight)) present in the cream, and optionally further comprising excipients chosen between zinc oxide, glycerine, caffeine, tocopherol, lecithin, waterpuncite, silica aluminate, sepiolite, essences and natural active principles, seaweeds, active thermal water.

The thermal mud develop on the skin zone an action that can be compared to the bioreactor so to allow for a faster passage of the substance in layers deeper than subcutaneous, in particular in adipose cell, and induce in the latter modifications of state.

Actually the adipose cell is a metabolically active cell playing a central role in controlling the energetic balance of the organism. In its membrane the receptors are present to which different hormones having lipogenetic (insulin, estrogens) or lipolytic (thyroidal, surrenalic, androgen hormones) bind.

Triterpenic saponins and in particular Pyro-Glu-Tyr-Proamide tripeptide, appearing to be very similar to human TRH, being different only because of the substitution of tirosine with istadine in position 2, contained in alfalfa herb, develop a strong lipolytic function.

Melatonine has a sinergistic action with alfalfa herb that in turn stimulates the functions of the pineal gland producing endogenous melatonine and is responsible of the neuro-immuno-endocrino maintenance controlling the biological clock in man.

Melatonine for topical use has an important antioxidant effect over the skin useful in the treatment of skin aging.

If muds are not used in the thermal site, with the described effects of the natural bio-reactor, it is possible as an alternative to use inert natural muds with the addition of alfalfa herb and melatonine at the same concentration than that of the cream.

Anti-cellulite effect manifests through the lipolytic action developed at a regional level by the substances applied on the skin with removal of fats by digestion or urines.

EXAMPLE 6 Protocol of Application of the Formulation According to the Invention and Results

Some volunteers with an age comprised between 20 and 70 years were recruited. The recluted patients were subjected to the following screening before and after the treatment:

-   -   Emocrome with leucocitary formula; azotemy; creatininemy;         glycemy; colesterol; HDL; LDL; triglycerids; amilasi; lipasi;         transaminasi; Ft₃; Ft₄;     -   TSH; electrolites (Ca, Na, K, Fe,);     -   Plicometric exam;     -   Measurement of the circumferences;     -   Impedenzometric exam;     -   DEXA;     -   Ecography; and     -   Photographic exam.

The formulation, in form of a cream, was applied on the interested skin zone and massaged for at least 20 minutes, so to allow a complete absorption. This time being passed, on the same zone muds were applied, keeping it covered with a suitable plastic sheath for at least 20-30 minutes.

This time being passed, the patient was allowed to have a shower. The treatment was performed ⅔ times a week until 15 application were made.

During the treatment, the patient were required to maintain the same alimentary habits and lifestyle.

Clinical applications were performed in two centres, applying the same criteria of selection and evaluation of the patients.

A first group of patients was treated in the private medical ambulatory of the Prof. Giulio Bellipanni, in collaboration with the University of Roma—Tor Vergata, Policlinico Universitario.

A second group of patients was treated in the private Clinical centre Marc Messegué Health Center of Melezzole (TR), with daily treatments for 7/10 days.

The first group of patients, composed by 14 people of age comprised between 21 and 65 years (average age 39 years), was subjected to a study in order to evaluate the possible variation of the weight of fat mass, of lean mass and of the percentage of body fat after topical application of the formulation according to the present invention.

The formulation, in form of a cream, was applied twice every week for an average time of 45 days.

All the recruited patient were subjected to a preliminary medical visit and clinical and instrumental controls. In particular, in collaboration with the ambulatory of endocrinology of University of Tor Vergata, DEXA exam was performed before and after the treatments to evaluate their efficacy.

DEXA exam is based on the principle of differential attenuation of a beam of X-rays at two energetic levels, when passing through the tissues. This attenuation was registered and correlated to the body composition of the subject. DEXA exam allows to evaluate, in a very reliable way and only little influenced by differences due to the operator, the weight and percentage of fat mass and lean mass in different body zones.

The analysis of the data collected by DEXA exam showed a decrease of the weight of fat mass in 7 patients, corresponding to 50% of the sample, an increase of lean mass in 6 patients, corresponding to 43% of the sample, and a decrease of the percentage of fat in 7 patients, corresponding to 50% of the sample treated.

As a whole, it was measured a loss of weight of fat mass of 8.806.2 grams, corresponding to 7.4% of the average weight of the fat mass at first control. On the contrary lean mass increased as a whole of 7.688.9 grams, corresponding to 3.6% of the weight of lean mass at first control.

In 50% of the patients treated a decrease of the weight and of the fat mass was detected assessable as an average of 7.4%, and a decrease of the percentage of fat of 50%.

The second group of patients, treated at Marc Messegué Health Center and composed by 10 patients of age comprised between 23 and 69 years (average age 41 years), was studied in order to evaluate possible variations of the weight of fat mass, of lean mass and of the percentage of body fat after topical application of the formulation in cream according to the invention for 7/10 days.

All the recruited patients were subjected to a preliminary medical visit and clinical and instrumental controls.

The analysis of the data collected by means of impedenziometric exam, before and after the cycle of applications, showed a decrease of the weight of fat mass in 8 patients, corresponding to 89% of the sample, an increase of lean mass in 6 patients, corresponding to 67% of the sample, and a decrease of the percentage of fat in 7 patients, corresponding to 78% of the sample treated.

As a whole, it was measured a loss of weight of fat mass of 9.900 grams, corresponding to 5.4% of the average weight of the fat mass at first control, while lean mass increased as a whole of 10.000 grams, corresponding to 5.8% of the weight of lean mass at first control.

Abdominal circumference detected at the level of the navel showed an average decrease of 3 cm on 80% of the sample. Only in two occasions it was not shown a decrease of the circumference.

Also plicometric exam of 8 standard measure showed an average decrease of 3.5% on 80% of the sample.

The present invention was described for illustrative, non-limitative purposes, according to its preferred embodiments, but it is to be understood that any variation and/or modification can be made by the skilled in the art without for this reason escaping the relative scope of protection, as defined by the enclosed claims. 

1. Topical formulation for the treatment of cellulite characterised in that it comprises alfalfa herb and derivatives thereof.
 2. Formulation according to claim 1, characterised in that it further comprise melatonine.
 3. Formulation according to claim 1 or 2, characterised in that said alfalfa herb derivatives comprise Pyro-Glu-Tyr-Proamide tripeptide.
 4. Formulation according to any of the previous claims, characterised in that said alfalfa herb is present according to a concentration comprised between 5 and 40% by weight.
 5. Formulation according to claim 4, characterised in that said alfalfa herb is present according to a concentration comprised between 10 and 20% by weight.
 6. Formulation according to claim 2, characterised in that the concentration of said melatonine is comprised in a range between 0 and 0.1% by weight.
 7. Formulation according to claim 6, characterised in that the concentration of said melatonine is comprised in a range between 0.01 and 0.05% by weight.
 8. Formulation according to any of the previous claims, characterised in that it further comprises water, excipients and other natural substances chosen amongst ginkgo bilobate, avocado, blueberry, centella, fucus, glycerine, caffeine, extract of Centella asiatica, escina, tocopherol, dextrin, lecithin, tocopherol acetate, phospholipids, cyclodextrins, oils and natural active principles.
 9. Method for the application of a topical formulation for the treatment of cellulite as defined in claims 1-8, characterised in that said formulation is applied on the skin, in the zones interested by cellulite and/or localized adiposity, massaging until complete absorption of the formulation.
 10. Method according to claim 9, characterised in that after application of said formulation, on the zones of skin previously treated vegetal or mineral mud is applied.
 11. Method according to claim 10, characterised in that said vegetal or mineral mud is enriched with alfalfa herb.
 12. Method according to claim 11, characterised in that said vegetal or mineral mud is further enriched with melatonine.
 13. Method according to claim 11 or 12, characterised in that said vegetal or mineral mud is further enriched with excipients chosen between ginkgo bilobate, avocado, blueberry, centella, fucus, zinc oxide, glycerine, caffeine, tocopherol, lecithin, waterpuncite, silica aluminate, sepiolite, essences and natural active principles, seaweeds, active thermal water.
 14. Pharmaceutical kit for the treatment of the cellulite comprising a formulation as defined in claims 1-8, together with vegetal or mineral mud, charged with alfalfa herb.
 15. Pharmaceutical kit according to claim 14, characterised in that said vegetal or mineral mud further comprises melatonine.
 16. Pharmaceutical kit according to claim 14 or 15, characterised in that said vegetal or mineral mud further comprises excipients chosen between ginkgo bilobate, avocado, blueberry, centella, fucus, zinc oxide, glycerine, caffeine, tocopherol, lecithin, waterpuncite, silica aluminate, sepiolite, essences and natural active principles, seaweeds, active thermal water.
 17. Pharmaceutical kit according to any of claims 14-16, characterised in that said alfalfa herb is present in the muds according to a concentration comprised between 5 and 10% by weight.
 18. Pharmaceutical kit according to claim 15, characterised in that said melatonine is present in the muds according to a concentration comprised between 0.001 and 0.005% by weight. 